China’s Payer Keeps Deep Price Cuts Steady in Latest NRDL Listing

Volume/Pricing Trade-Off

 
• By Dexter Jie Yan
  
2022 round NRDL price talk
36% more novel drugs win national reimbursement in latest annual China negotiations • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from China

More from Focus On Asia